Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Greg was also central to the planning, design, and construction of this facility
Subscribe To Our Newsletter & Stay Updated